Showing results (21-30 of 157) with videos related to
Sort By:
Pageof 16
Clinical Lung Cancer|July 27, 2017
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung CancerJames Chih-Hsin Yang, Tony Mok, Baohui Han, et al.Lung Cancer (Amsterdam, Netherlands)|September 24, 2008
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overviewHatem A Azim, Inas Elattar, Fausto R Loberiza, et al.Lung Cancer (Amsterdam, Netherlands)|December 23, 2023
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)Cesare Gridelli, Solange Peters, Tony Mok, et al.Oncotargets and Therapy|November 9, 2013
Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smokingQiang Tan, Guan Wang, Jia Huang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.Journal of Cellular and Molecular Medicine|December 18, 2009
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisLuis Paz-Ares, Denis Soulières, Ivan Melezínek, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 3, 2010
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancerTony Mok, Yi-long Wu, Joseph Siu-kie Au, et al.Frontiers in Oncology|January 28, 2026
Unlocking the potential of immunotherapy for patients with resectable non-small cell lung cancerSandip Pravin Patel, Justin Gainor, Steven Kao, et al.Future Oncology (London, England)|February 11, 2021
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinibEdward S Kim, Fabrice Barlesi, Tony Mok, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2025
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)Cesare Gridelli, Tony Mok, Pasi Jänne, et al.Pageof 16